Bibliographie

[1] Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205–15.
[2] Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984;27:459–61.
[3] Giannaccare G. Blood derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci 2017;56:595–604.
[4] Daniel Nelson J, Gordon JF, Chiron Keratoconjunctivitis Sicca Study Group. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Am J Ophthalmol 1992;114:441–7.
[5] Liu L. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol 2005;243:706–14.
[6] Marks DC, van der Meer PF. the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Serum eye drops : a survey of international production methods. Vox Sang 2017;112:310–7.
[7] Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004;88:1467–74.
[8] Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999;106:1984–9.
[9] Poon AC. Autologous serum eyedrops for dry eyes and epithelial defects : clinical and in vitro toxicity studies. Br J Ophthalmol 2001;85:1188–97.
[10] Cho YK, Huang W, Kim GY, Lim BS. Comparison of autologous serum eye drops with different diluents. Curr Eye Res 2013;38:9–17.
[11] Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2017;CD009327.
[12] Wang L. Autologous serum eye drops versus artificial tear drops for dry eye disease : a systematic review and meta-analysis of randomized controlled trials. Ophthalmic Res 2020;63:443–51.
[13] Franchini M. Serum eye drops for the treatment of ocular surface diseases : a systematic review and meta-analysis. Blood Transfus 2019;17:200–9.
[14] Celebi ARC, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome : a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol 2014;252:619–26.
[15] Jeng BH, Dupps WJ. Autologous serum 50 % eyedrops in the treatment of persistent corneal epithelial defects. Cornea 2009;28:1104–8.
[16] Özbek-Uzman S, Yalnız-Akkaya Z, Şingar Özdemir E, Burcu A. Treatment of persistent epithelial defects with single-dose autologous serum eye drops. Eur J Ophthalmol 2022;32:2159–65.
[17] Rocha EM, Pelegrino FSA, de Paiva CS, et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000;25:1101–3.
[18] Matsumoto Y. Autologous serum application in the treatment of neurotrophic keratopathy*1. Ophthalmology 2004;111:1115–20.
[19] Ziakas NG. Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clin Experiment Ophthalmol 2010;38:683–7.
[20] López-García JS, Rivas L, García-Lozano I, Murube J. Autologous serum eyedrops in the treatment of aniridic keratopathy. Ophthalmology 2008;115:262–7.
[21] Akyol-Salman İ. Effects of autologous serum eye drops on corneal wound healing after superficial keratectomy in rabbits. Cornea 2006;25:1178–81.
[22] Chen YM. The Effect of topical autologous serum on graft re-epithelialization after penetrating keratoplasty. Am J Ophthalmol 2010;150:352–359.e2.
[23] Kang NH, Lee S, Jun RM. Comparison of epitheliotrophic factors in autologous serum eyedrops from sera of chronic renal failure patients vs. normal controls. Graefes Arch Clin Exp Ophthalmol 2015;253:1705–12.
[24] Harloff S. Epitheliotrophe Kapazität von Serum-Augentropfen gesunder versus immunsupprimierter Patienten mit rheumatoider Arthritis. Klin Monatsblätter Für Augenheilkd 2008;225:200–6.
[25] Anitua E. Plasma rich in growth factors for the treatment of ocular surface diseases. Curr Eye Res 2016;41:875–82.
[26] Anitua E. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res 2015;135:118–26.
[27] Anitua E, Muruzabal F, Alcalde I, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery. Exp Eye Res 2013;115:153–61.
[28] Soifer M. A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America. Ocul Surf 2022;25:40–8.
[29] García-Conca V. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol (Copenh) 2019;97:e170–8.
[30] López-Plandolit S, Morales MC, Freire V, et al. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea 2010;29:843–8.
[31] Alio JL, Colecha JR, Pastor S, et al. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res 2007;39:124–9.
[32] Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol 2012;56:544–50.
[33] Sánchez-Ávila RM. Use of plasma rich in growth factors and regenerating agent matrix for the treatment of corneal diseases. Vis Basel Switz 2021;5:34.
[34] Wang M, Yennam S, Pflugfelder S. Initial experiences using plasma rich in growth factors to treat keratoneuralgia. Front Med 2022;9, 946828.
[35] Barros A. Recovery of corneal innervation after treatment in dry eye disease : a confocal microscopy study. J Clin Med 2023;12:1841.